JP2015527978A5 - - Google Patents

Download PDF

Info

Publication number
JP2015527978A5
JP2015527978A5 JP2015518629A JP2015518629A JP2015527978A5 JP 2015527978 A5 JP2015527978 A5 JP 2015527978A5 JP 2015518629 A JP2015518629 A JP 2015518629A JP 2015518629 A JP2015518629 A JP 2015518629A JP 2015527978 A5 JP2015527978 A5 JP 2015527978A5
Authority
JP
Japan
Prior art keywords
seq
sequence number
cancer
antibody
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015518629A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015527978A (ja
JP6438391B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/047192 external-priority patent/WO2013192596A2/en
Publication of JP2015527978A publication Critical patent/JP2015527978A/ja
Publication of JP2015527978A5 publication Critical patent/JP2015527978A5/ja
Application granted granted Critical
Publication of JP6438391B2 publication Critical patent/JP6438391B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015518629A 2012-06-22 2013-06-21 Ccr2に結合する抗原結合タンパク質 Expired - Fee Related JP6438391B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261663496P 2012-06-22 2012-06-22
US61/663,496 2012-06-22
PCT/US2013/047192 WO2013192596A2 (en) 2012-06-22 2013-06-21 Antigen binding proteins that bind ccr2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018141655A Division JP2018199681A (ja) 2012-06-22 2018-07-27 Ccr2に結合する抗原結合タンパク質

Publications (3)

Publication Number Publication Date
JP2015527978A JP2015527978A (ja) 2015-09-24
JP2015527978A5 true JP2015527978A5 (enExample) 2016-08-12
JP6438391B2 JP6438391B2 (ja) 2018-12-12

Family

ID=49769736

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015518629A Expired - Fee Related JP6438391B2 (ja) 2012-06-22 2013-06-21 Ccr2に結合する抗原結合タンパク質
JP2018141655A Withdrawn JP2018199681A (ja) 2012-06-22 2018-07-27 Ccr2に結合する抗原結合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018141655A Withdrawn JP2018199681A (ja) 2012-06-22 2018-07-27 Ccr2に結合する抗原結合タンパク質

Country Status (7)

Country Link
US (3) US9315579B2 (enExample)
EP (1) EP2864358B1 (enExample)
JP (2) JP6438391B2 (enExample)
CN (1) CN105051065A (enExample)
CA (1) CA2877814A1 (enExample)
HK (1) HK1208236A1 (enExample)
WO (1) WO2013192596A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6141864B2 (ja) 2011-12-01 2017-06-07 ケモセントリックス,インコーポレイティド Ccr(4)アンタゴニストとしての置換アニリン
JP6429771B2 (ja) * 2012-06-21 2018-11-28 ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. c−Metに結合する抗原結合タンパク質
WO2013192596A2 (en) 2012-06-22 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind ccr2
PT3297438T (pt) 2015-05-21 2022-01-25 Chemocentryx Inc Moduladores de ccr2
WO2017165125A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer
US20170348442A1 (en) 2016-06-02 2017-12-07 Washington University Compositions and methods for detecting ccr2 receptors
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
JP2020517256A (ja) * 2017-04-19 2020-06-18 エルスター セラピューティクス, インコーポレイテッド 多重特異性分子およびその使用
MA50665A (fr) 2017-09-25 2020-08-05 Chemocentryx Inc Polythérapie utilisant un antagoniste du récepteur 2 de la chimiokine (ccr2) et un inhibiteur pd-1/pd-l1
EP3720881A1 (en) 2017-12-08 2020-10-14 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
IL275898B2 (en) 2018-01-08 2025-05-01 Chemocentryx Inc Methods for treating solid tumors with CCR2 antagonists
US20210317461A1 (en) 2018-08-09 2021-10-14 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
CN113164777B (zh) 2018-09-27 2024-12-13 马伦戈治疗公司 Csf1r/ccr2多特异性抗体
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
AU2022378899A1 (en) 2021-10-27 2024-03-07 Granite Bio Ag Antibodies targeting ccr2
WO2024220548A2 (en) * 2023-04-17 2024-10-24 University Of Southern California Molecular-mri using ccr2-targeted micelles for detection of lymph node metastases
WO2024245988A1 (en) 2023-05-29 2024-12-05 Granite Bio Ag Antibodies targeting ccr2
WO2025231346A1 (en) * 2024-05-03 2025-11-06 The Wistar Institute Of Anatomy And Biology Anti-interferon-alpha and anti-interferon-beta antibodies, and methods of use thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化b−b10
DE69332377T2 (de) 1992-07-13 2003-07-03 Bionebraska, Inc. Verfahren zur modifizierung rekombinanter polypeptide
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
ATE240394T1 (de) 1992-10-23 2003-05-15 Immunex Corp Methoden zur herstellung löslicher, oligomerer proteine
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6541208B1 (en) 1998-03-17 2003-04-01 University Of Maryland Biotechnology Institute Diagnostic method for distinguishing HIV-associated dementia from other forms of dementia
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
GB0016138D0 (en) 2000-06-30 2000-08-23 Novartis Ag Organic compounds
ATE516820T1 (de) 2000-09-29 2011-08-15 Schering Corp Pegyliertes interleukin 10
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20070021466A1 (en) 2002-11-18 2007-01-25 Solomon Ungashe CCR2 inhibitors and methods of use thereof
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
US20060205761A1 (en) 2003-06-06 2006-09-14 Catherine Abbadie Ccr-2 antagonists for treatment of neuropathic pain
JP2007521248A (ja) * 2003-12-10 2007-08-02 ミレニアム ファーマシューティカルズ, インコーポレイテッド ヒト化抗ccr2抗体および該抗体を使用する方法
US20050260139A1 (en) * 2004-03-30 2005-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on anticholinergics and CCR2 receptor antagonists
CA2665808A1 (en) * 2006-10-05 2008-05-22 Centocor Ortho Biotech Inc. Ccr2 antagonists for treatment of fibrosis
KR101772706B1 (ko) * 2008-08-18 2017-08-29 화이자 인크. Ccr2에 대한 항체
WO2013192596A2 (en) * 2012-06-22 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind ccr2

Similar Documents

Publication Publication Date Title
CN105837688B (zh) 单域抗体及其编码基因,免疫毒素及其编码基因、制备方法、表达载体、应用,及宿主细胞
RU2016136639A (ru) Антитела против эотаксина 2, которые распознают дополнительные связывающие CCR3 хемокины
HRP20200241T1 (hr) Anti-c5a vezujuće skupine s visokom blokirajućom aktivnosti
JP2012501669A5 (enExample)
JP2020500542A5 (enExample)
JP2016515524A5 (enExample)
JP2012500020A5 (enExample)
RU2009128215A (ru) Человеческие антитела, которые связываются с человеческим il-12, и способы получения
TN2015000348A1 (en) Antibodies that bind il-23
JP2014500009A5 (enExample)
RU2011135422A (ru) Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний
EA201370105A1 (ru) Человеческие антитела против человеческого tnf-подобного лиганда-1а (tl1a)
JP2017523984A5 (enExample)
JP2019524730A5 (enExample)
JP2017512838A5 (enExample)
RU2015144033A (ru) Антитела против cd25 и их применения
EA201300418A1 (ru) Антитела к человеческому tweak и варианты их применения
RU2019126888A (ru) Антитело к человеческому аннексину а1
JP2016520595A5 (enExample)
Chan et al. Affinity maturation: highlights in the application of in vitro strategies for the directed evolution of antibodies
CN106188298A (zh) 一种Vsig4纳米抗体及其抗原表位鉴定方法和应用
JP2019516785A5 (enExample)
Yu et al. Rapid isolation of pan-neutralizing antibodies against Omicron variants from convalescent individuals infected with SARS-CoV-2
CN119060194A (zh) 一种靶向b细胞的双特异性纳米抗体及其应用
JP2020505465A5 (enExample)